Research Paper Volume 12, Issue 10 pp 9224—9239

Figure 3. PI3K phosphorylation is involved in APLN-induced IL-1β synthesis. (A) OASFs were pretreated with PI3K inhibitors (LY294002, Wortmannin; 10 μM) for 30 min, then incubated with APLN (10 ng/mL) for 24 h. IL-1β mRNA and protein levels were examined by RT-qPCR (n=4) and Western blot (n=3) assays, respectively. (B) OASFs were pretreated with PI3K inhibitors (LY294002, Wortmannin; 10 μM) for 30 min, then incubated with APLN (10 ng/mL) for 24 h. Excreted IL-1 β protein levels were examined by ELISA (n=5). (C) OASFs were transfected with PI3K siRNA (1 μg) then incubated with APLN (10 ng/mL) for 24 h. IL-1β mRNA levels were examined by ELISA assay (n=5). (D) OASFs were transfected with PI3K siRNA (1 μg), then incubated with APLN (10 ng/mL) for 24 h. Excreted IL-1β protein levels were examined by ELISA assay (n=5). (E) OASFs were incubated with APLN for the indicated time intervals, and the extent of PI3K phosphorylation was examined by Western blot (n=3). * p<0.05 compared with control group; # p<0.05 compared with the APLN-treated group.